UPDATE : Friday, August 7, 2020
HOME Pharma
GC LabCell releases clinical results of NK cell therapy
  • By Shim Hyun-tai
  • Published 2020.06.11 17:34
  • Updated 2020.06.11 17:34
  • comments 0

GC LabCell has unveiled the study data of the combined therapy of its natural killer cell treatment, which is regarded as the next-generation immuno-oncology.

The company said Thursday that it would also present the interim result of the combined therapy of NK cell treatment, MG4101, and antibody cancer drug, Rituximab, at the European Hematology Association's online conference from June 11-21.

The therapeutic effect of NK cell, which attacks cancer cells or viruses in the body, maximizes when combined with an antibody-drug. Although many studies are being conducted globally, few have yet to prove the efficacy by using cultured NK cells with antibodies.

MG4101 removes cancer cells by using natural killer cells, which are innate immune cells in the body, GC LabCell said. It can be used without any side effects to patients because of its high purity and can be mass-produced thanks to the company's culture technology, it added.

Studies on patients with lymphoma have shown excellent interim results in the efficacy and safety of the combination therapy of MG4101 and Rituximab. As a result of the administration, 50 percent of all patients showed a partial response, and there were no side effects such as dose-limiting toxicity.

GC LabCell explained that its combination therapy might become a significant therapeutic option for patients with lymphoma, as this clinical study was conducted on patients who failed with existing treatment.

"MG4101 is steadily increasing its potential for the development of combined administration with antibody therapeutics," said Hwang Yu-kyung, director of GC Labcell's Cell Therapy Research Center. "We will speed up the development of next-generation NK cell therapy products by making the most of our capabilities in mass production and cryopreservation."


<© Korea Biomedical Review, All rights reserved.>

Other articles by Shim Hyun-tai
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top